Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

NCT00690872 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
DRUG: carboplatin
DRUG: gemcitabine hydrochloride
GENETIC: polymerase chain reaction
OTHER: fluorescence activated cell sorting
OTHER: immunoenzyme technique

Sponsor

National Cancer Centre, Singapore